Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion type Assertion NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_head.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion evidence source_evidence_literature NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion SIO_000772 21641642 NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion wasDerivedFrom befree-20150227 NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.
- NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion wasGeneratedBy ECO_0000203 NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.